Use of medications in Wolff-Parkinson-White syndrome.
Identifieur interne : 001173 ( PubMed/Checkpoint ); précédent : 001172; suivant : 001174Use of medications in Wolff-Parkinson-White syndrome.
Auteurs : D P Redfearn [Canada] ; A D Krahn ; A C Skanes ; R. Yee ; G J KleinSource :
- Expert opinion on pharmacotherapy [ 1744-7666 ] ; 2005.
English descriptors
- KwdEn :
- MESH :
- chemical , classification : Anti-Arrhythmia Agents.
- chemical , therapeutic use : Anti-Arrhythmia Agents.
- drug effects : Electrocardiography.
- drug therapy : Wolff-Parkinson-White Syndrome.
- physiopathology : Wolff-Parkinson-White Syndrome.
- Humans.
Abstract
The diagnosis of Wolff-Parkinson-White syndrome is generally straightforward; however, the management may not be, and requires an understanding of the competing risks of various treatment options and that of the clinical setting in which the diagnosis is made. The symptomatic patient with Wolff-Parkinson-White has an increased risk of atrial fibrillation and a small but significant risk of sudden cardiac death. Therapy is based on reduction in symptom burden and attenuation of the risk of pre-excited atrial fibrillation. Catheter ablation is the most effective means of achieving this goal with abolition of symptoms and risk of pre-excited atrial fibrillation. Medication is often employed in the acute setting to terminate paroxysms of arrhythmia associated with the accessory pathway and reduce the subsequent burden of symptoms until ablation can be performed. An overview of the agents commonly used is provided together with recommendations.
DOI: 10.1517/14656566.6.6.955
PubMed: 15952923
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15952923Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of medications in Wolff-Parkinson-White syndrome.</title><author><name sortKey="Redfearn, D P" sort="Redfearn, D P" uniqKey="Redfearn D" first="D P" last="Redfearn">D P Redfearn</name><affiliation wicri:level="1"><nlm:affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Krahn, A D" sort="Krahn, A D" uniqKey="Krahn A" first="A D" last="Krahn">A D Krahn</name></author><author><name sortKey="Skanes, A C" sort="Skanes, A C" uniqKey="Skanes A" first="A C" last="Skanes">A C Skanes</name></author><author><name sortKey="Yee, R" sort="Yee, R" uniqKey="Yee R" first="R" last="Yee">R. Yee</name></author><author><name sortKey="Klein, G J" sort="Klein, G J" uniqKey="Klein G" first="G J" last="Klein">G J Klein</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15952923</idno><idno type="pmid">15952923</idno><idno type="doi">10.1517/14656566.6.6.955</idno><idno type="wicri:Area/PubMed/Corpus">001259</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001259</idno><idno type="wicri:Area/PubMed/Curation">001259</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001259</idno><idno type="wicri:Area/PubMed/Checkpoint">001259</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001259</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Use of medications in Wolff-Parkinson-White syndrome.</title><author><name sortKey="Redfearn, D P" sort="Redfearn, D P" uniqKey="Redfearn D" first="D P" last="Redfearn">D P Redfearn</name><affiliation wicri:level="1"><nlm:affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Krahn, A D" sort="Krahn, A D" uniqKey="Krahn A" first="A D" last="Krahn">A D Krahn</name></author><author><name sortKey="Skanes, A C" sort="Skanes, A C" uniqKey="Skanes A" first="A C" last="Skanes">A C Skanes</name></author><author><name sortKey="Yee, R" sort="Yee, R" uniqKey="Yee R" first="R" last="Yee">R. Yee</name></author><author><name sortKey="Klein, G J" sort="Klein, G J" uniqKey="Klein G" first="G J" last="Klein">G J Klein</name></author></analytic><series><title level="j">Expert opinion on pharmacotherapy</title><idno type="eISSN">1744-7666</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Arrhythmia Agents (classification)</term><term>Anti-Arrhythmia Agents (therapeutic use)</term><term>Electrocardiography (drug effects)</term><term>Humans</term><term>Wolff-Parkinson-White Syndrome (drug therapy)</term><term>Wolff-Parkinson-White Syndrome (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Anti-Arrhythmia Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Arrhythmia Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Electrocardiography</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Wolff-Parkinson-White Syndrome</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Wolff-Parkinson-White Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The diagnosis of Wolff-Parkinson-White syndrome is generally straightforward; however, the management may not be, and requires an understanding of the competing risks of various treatment options and that of the clinical setting in which the diagnosis is made. The symptomatic patient with Wolff-Parkinson-White has an increased risk of atrial fibrillation and a small but significant risk of sudden cardiac death. Therapy is based on reduction in symptom burden and attenuation of the risk of pre-excited atrial fibrillation. Catheter ablation is the most effective means of achieving this goal with abolition of symptoms and risk of pre-excited atrial fibrillation. Medication is often employed in the acute setting to terminate paroxysms of arrhythmia associated with the accessory pathway and reduce the subsequent burden of symptoms until ablation can be performed. An overview of the agents commonly used is provided together with recommendations.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15952923</PMID><DateCreated><Year>2005</Year><Month>06</Month><Day>14</Day></DateCreated><DateCompleted><Year>2006</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2005</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Use of medications in Wolff-Parkinson-White syndrome.</ArticleTitle><Pagination><MedlinePgn>955-63</MedlinePgn></Pagination><Abstract><AbstractText>The diagnosis of Wolff-Parkinson-White syndrome is generally straightforward; however, the management may not be, and requires an understanding of the competing risks of various treatment options and that of the clinical setting in which the diagnosis is made. The symptomatic patient with Wolff-Parkinson-White has an increased risk of atrial fibrillation and a small but significant risk of sudden cardiac death. Therapy is based on reduction in symptom burden and attenuation of the risk of pre-excited atrial fibrillation. Catheter ablation is the most effective means of achieving this goal with abolition of symptoms and risk of pre-excited atrial fibrillation. Medication is often employed in the acute setting to terminate paroxysms of arrhythmia associated with the accessory pathway and reduce the subsequent burden of symptoms until ablation can be performed. An overview of the agents commonly used is provided together with recommendations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Redfearn</LastName><ForeName>D P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krahn</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Skanes</LastName><ForeName>A C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>G J</ForeName><Initials>GJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000889" MajorTopicYN="N">Anti-Arrhythmia Agents</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014927" MajorTopicYN="N">Wolff-Parkinson-White Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>52</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15952923</ArticleId><ArticleId IdType="doi">10.1517/14656566.6.6.955</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Klein, G J" sort="Klein, G J" uniqKey="Klein G" first="G J" last="Klein">G J Klein</name><name sortKey="Krahn, A D" sort="Krahn, A D" uniqKey="Krahn A" first="A D" last="Krahn">A D Krahn</name><name sortKey="Skanes, A C" sort="Skanes, A C" uniqKey="Skanes A" first="A C" last="Skanes">A C Skanes</name><name sortKey="Yee, R" sort="Yee, R" uniqKey="Yee R" first="R" last="Yee">R. Yee</name></noCountry><country name="Canada"><noRegion><name sortKey="Redfearn, D P" sort="Redfearn, D P" uniqKey="Redfearn D" first="D P" last="Redfearn">D P Redfearn</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001173 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001173 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15952923
|texte= Use of medications in Wolff-Parkinson-White syndrome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15952923" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |